Literature DB >> 28190390

Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics.

Da-Yong Lu1, Rong-Xin Qu2, Ting-Ren Lu1, Hong-Ying Wu1.   

Abstract

BACKGROUND: Last two to three decades, this world witnesses a rapid progress of biomarkers and bioinformatics technologies. Cancer bioinformatics is one of such important omics branches for experimental/clinical studies and applications.
METHODS: Same as other biological techniques or systems, bioinformatics techniques will be widely used. But they are presently not omni-potent. Despite great popularity and improvements, cancer bioinformatics has its own limitations and shortcomings at this stage of technical advancements.
RESULTS: This article will offer a panorama of bioinformatics in cancer researches and clinical therapeutic applications-possible advantages and limitations relating to cancer therapeutics. A lot of beneficial capabilities and outcomes have been described. As a result, a successful new era for cancer bioinformatics is waiting for us if we can adhere on scientific studies of cancer bioinformatics in malignant- origin mining, medical verifications and clinical diagnostic applications.
CONCLUSION: Cancer bioinformatics gave a great significance in disease diagnosis and therapeutic predictions. Many creative ideas and future perspectives are highlighted. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Cancer bioinformatics; cancer stem cells; cancer therapy; drug developments; drug response predictions; neoplasmzzm321990metastasis; personalized cancer therapy

Mesh:

Substances:

Year:  2017        PMID: 28190390     DOI: 10.2174/1574887112666170209161444

Source DB:  PubMed          Journal:  Rev Recent Clin Trials        ISSN: 1574-8871


  4 in total

1.  Diagnostic and prognostic value of thymidylate synthase expression in breast cancer.

Authors:  Shaoran Song; Bixia Tian; Miao Zhang; Xiaoqian Gao; Liu Jie; Peijun Liu; Juan Li
Journal:  Clin Exp Pharmacol Physiol       Date:  2020-10-24       Impact factor: 2.557

2.  Identification of Hub Gene TIMP1 and Relative ceRNAs Regulatory Network in Colorectal Cancer.

Authors:  Ya-Fei Qin; Guang-Ming Li; Grace Wang; De-Jun Kong; Hong-Da Wang; Yi-Ming Zhao; Jing-Peng Hao; Hong Qin; Da-Qing Sun; Hao Wang
Journal:  Ther Clin Risk Manag       Date:  2021-08-27       Impact factor: 2.423

3.  Systems Network Pharmacology-Based Prediction and Analysis of Potential Targets and Pharmacological Mechanism of Actinidia chinensis Planch. Root Extract for Application in Hepatocellular Carcinoma.

Authors:  Yue Hu; Liang Yang; Yunfei Lu; Yong Wang; Jianshuai Jiang; Yahui Liu; Qing Cao
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-20       Impact factor: 2.650

4.  Bioinformatics combined with quantitative proteomics analyses and identification of potential biomarkers in cholangiocarcinoma.

Authors:  Yanyan Lin; Wenbo Meng; Zijian Da; Long Gao; Gang Su; Jia Yao; Wenkang Fu; Jinduo Zhang; Xu Zhang; Zhaoji Pei; Ping Yue; Bing Bai; Xun Li
Journal:  Cancer Cell Int       Date:  2020-04-22       Impact factor: 5.722

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.